(Q33642155)

English

MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

28 July 2017

MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema (English)

1 reference

Europe PubMed Central

28 July 2017

1 reference

based on heuristic

inferred from title

author name string

Francine M Gregoire

1

1 reference

Europe PubMed Central

28 July 2017

Fang Zhang

2

1 reference

Europe PubMed Central

28 July 2017

Holly J Clarke

3

1 reference

Europe PubMed Central

28 July 2017

Thomas A Gustafson

4

1 reference

Europe PubMed Central

28 July 2017

Dorothy D Sears

5

1 reference

Europe PubMed Central

28 July 2017

Svetlana Favelyukis

6

1 reference

Europe PubMed Central

28 July 2017

James Lenhard

7

1 reference

Europe PubMed Central

28 July 2017

Dennis Rentzeperis

8

1 reference

Europe PubMed Central

28 July 2017

L Edward Clemens

9

1 reference

Europe PubMed Central

28 July 2017

Yi Mu

10

1 reference

Europe PubMed Central

28 July 2017

Brian E Lavan

11

1 reference

Europe PubMed Central

28 July 2017

publication date

23 April 2009

1 reference

Europe PubMed Central

28 July 2017

Molecular Endocrinology

1 reference

Europe PubMed Central

28 July 2017

23

1 reference

Europe PubMed Central

28 July 2017

7

1 reference

Europe PubMed Central

28 July 2017

975-988

1 reference

Europe PubMed Central

28 July 2017

TZDs and Bone: A Review of the Recent Clinical Evidence

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

21 June 2018

Peroxisome proliferator-activated receptor gamma activation promotes infiltration of alternatively activated macrophages into adipose tissue.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

21 June 2018

Use of thiazolidinediones and fracture risk

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

21 June 2018

PPAR-gamma regulates osteoclastogenesis in mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

21 June 2018

Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

21 June 2018

The differential interactions of peroxisome proliferator-activated receptor gamma ligands with Tyr473 is a physical basis for their unique biological activities

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

21 June 2018

Partial agonists activate PPARgamma using a helix 12 independent mechanism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

21 June 2018

Skeletal consequences of thiazolidinedione therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

21 June 2018

Diabetes drug pioglitazone (Actos): risk of fracture

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

21 June 2018

S 26948: a new specific peroxisome proliferator activated receptor gamma modulator with potent antidiabetes and antiatherogenic effects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

21 June 2018

The next generation of PPAR drugs: do we have the tools to find them?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

21 June 2018

Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

21 June 2018

Evolution of peroxisome proliferator-activated receptor agonists

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

21 June 2018

Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

21 June 2018

Obesity, Inflammation, and Insulin Resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

21 June 2018

Transcriptional coregulators in the control of energy homeostasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

21 June 2018

Molecular basis of selective PPARgamma modulation for the treatment of Type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

21 June 2018

PPARs and molecular mechanisms of transrepression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

21 June 2018

Safety issues and prospects for future generations of PPAR modulators

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

21 June 2018

PPARgamma in immunity and inflammation: cell types and diseases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

21 June 2018

Selective Modulators of PPAR-gamma Activity: Molecular Aspects Related to Obesity and Side-Effects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

21 June 2018

Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

21 June 2018

Transcription coactivators for peroxisome proliferator-activated receptors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

21 June 2018

The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

21 June 2018

Halofenate is a selective peroxisome proliferator-activated receptor gamma modulator with antidiabetic activity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

21 June 2018

KR-62980: a novel peroxisome proliferator-activated receptor gamma agonist with weak adipogenic effects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

21 June 2018

Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

21 June 2018

A novel partial agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma) recruits PPARgamma-coactivator-1alpha, prevents triglyceride accumulation, and potentiates insulin signaling in vitro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

21 June 2018

A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

21 June 2018

Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

21 June 2018

A new class of peroxisome proliferator-activated receptor agonists with a novel binding epitope shows antidiabetic effects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

21 June 2018

Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

21 June 2018

Bone is a target for the antidiabetic compound rosiglitazone.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

21 June 2018

Effect of thiazolidinediones on glucose and fatty acid metabolism in patients with type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

21 June 2018

The metabolic syndrome: peroxisome proliferator-activated receptor gamma and its therapeutic modulation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

21 June 2018

PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

21 June 2018

PPAR(gamma) and glucose homeostasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

21 June 2018

Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

21 June 2018

A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

21 June 2018

The coregulator exchange in transcriptional functions of nuclear receptors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

21 June 2018

A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

21 June 2018

A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor gamma-activating properties

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

21 June 2018

Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

21 June 2018

Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

21 June 2018

Thiazolidinediones inhibit alkaline phosphatase activity while increasing expression of uncoupling protein, deiodinase, and increasing mitochondrial mass in C3H10T1/2 cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

21 June 2018

Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

21 June 2018

Effects of Halofenate on Glucose Tolerance in Patients with Hyperlipoproteinemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

21 June 2018

Comparison of clofibrate with halofenate in diabetics with hyperlipidaemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

21 June 2018

Anti-inflammatory and antidiabetic roles of PPARgamma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

30 October 2018

Diabetes drugs tied to fractures in women

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

30 October 2018

Structural and functional consequences of mitochondrial biogenesis in human adipocytes in vitro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

30 October 2018

Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

30 October 2018

Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

30 October 2018

Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

30 October 2018

RNA interfering approach for clarifying the PPARgamma pathway using lentiviral vector expressing short hairpin RNA.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

30 October 2018

An antidiabetic thiazolidinedione induces eccentric cardiac hypertrophy by cardiac volume overload in rats

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

30 October 2018

Abdominal fat distribution and peripheral and hepatic insulin resistance in type 2 diabetes mellitus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

30 October 2018

Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

30 October 2018

Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

30 October 2018

Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5419173

30 October 2018

Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/19389808

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Halofenate: an effective hypolipemia- and hypouricemia-inducing drug

1 reference

https://pubmed.ncbi.nlm.nih.gov/19389808

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of troglitazone on body fat distribution in type 2 diabetic patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/19389808

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A new thiazolidinedione, NC-2100, which is a weak PPAR-gamma activator, exhibits potent antidiabetic effects and induces uncoupling protein 1 in white adipose tissue of KKAy obese mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/19389808

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1210/ME.2008-0473

1 reference

Europe PubMed Central

28 July 2017

1 reference

Europe PubMed Central

28 July 2017

1 reference

Europe PubMed Central

28 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33642155&oldid=1980051611"